Regeneron to acquire 23andMe for $256m.

Regeneron, a biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases, agreed to acquire all of the assets of 23andMe, a human genetics and biotechnology company, for $256m. "Regeneron was one of the first biotech companies to bet its future on the power of DNA, fueling our drug discovery efforts so as to deliver some of the world’s leading and most innovative medicines, including treatments to prevent blindness, for allergic diseases from asthma to atopic dermatitis, for several forms of cancer, and even for Ebola and COVID-19," George D. Yancopoulos, Regeneron co-Founder, Board co-Chair, President and Chief Scientific Officer.